Insiders who reported open-market trades in the last 12 months at the companies Christopher Peetz files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Patrick J. Heron - $9.00M in MIRM purchases and sales in the last 12 months
Michael G. Grey - $7.20M in MIRM purchases and sales in the last 12 months
Jolanda Howe - $5.55M in MIRM purchases and sales in the last 12 months
Todd Watanabe - $4.44M in ARQT purchases and sales in the last 12 months
Eric Bjerkholt - $3.56M in MIRM purchases and sales in the last 12 months
Peter Radovich - $2.32M in MIRM purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Christopher Peetz is a corporate insider, tracked as CHIEF EXECUTIVE OFFICER, Director of Mirum Pharmaceuticals, Inc. (MIRM). InsiderAlpha holds 15 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Christopher Peetz submitted recently?
4 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Christopher Peetz been buying or selling stock?
Recorded transactions: 0 open-market purchases and 21 open-market sales ($20.98M) across all tracked filings.
Christopher Peetz is CHIEF EXECUTIVE OFFICER, Director of Mirum Pharmaceuticals, Inc. (MIRM). 15 SEC Form 4 filings on record going back to 2024, most recently on 7 October 2026. Most recent open-market trade: sold $2.15M of MIRM on 3 September 2026. Lifetime open-market sales: $20.98M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Christopher Peetz.
InsiderAlpha's records for Christopher Peetz go back to 2024: 15 primary Form 4 filings, an average of 5.0 per year. 23 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
